Marijuana is also referred to as marijuana, grass and bud however its proper name is clearly cannabis. It’s recognized as a prohibited substance in the US and many nations and possession of marijuana is a crime punishable by law. The FDA classifies marijuana as Schedule I, substances that have an extremely significant potential for abuse and have no tested medical usage. Over time several studies assert that some compounds found in marijuana have medicinal usage, specially in terminal illnesses such as cancer and AIDS. This started a ferocious debate over the advantages and disadvantages of using medical marijuana. To repay this debate, the Institute of Medicine published the famous 1999 IOM report entitled Marijuana and Medicine: Assessing the Science Base. The report was comprehensive but did not provide a very clear cut yes or no response. The opposite camps of the medical marijuana issue often cite part of their report within their advocacy arguments. However, although the report explained several things, it never depended on the controversy once and for all.
Let’s look at the problems that encourage why medical marijuana should be legalized.
(1) Pot is just a naturally occurring herb and it cannabidiol oil has been used by South America to Asia as a herbal medicine for millennia. In this era when the natural and organic are essential health buzz words, a naturally occurring herb like bud may possibly be more attractive to and more healthy for users than synthetic medication.
Several studies, as summarized in the IOM report, researchers have discovered that cannabis can be utilised as analgesic, e.g. to treat pain. A few studies demonstrated that THC, a marijuana component works well in treating chronic pain caused by cancer patients. However, studies on acute pain such as those experienced throughout surgery and injury possess inconclusive reports. A few studies, also outlined from the IOM report, have demonstrated that some marijuana components possess anti emetic properties and are, so, effective against nausea and vomitingthat can be normal side effects of cancer chemotherapy and radiation therapy. Some researchers are of the opinion that cannabis has some therapeutic potential against neurological diseases such as multiple sclerosis. Specific compounds extracted in marijuana possess strong therapeutic potential. Cannobidiol (CBD), a significant component of marijuana, was shown to have anti fungal, anti cancer and anti oxidant properties. Other cannabinoids have been demonstrated to prevent high blood pressure (IOP), a major risk factor for glaucoma. Drugs that contain ingredients found in bud but have already been synthetically produced from the lab are approved by the USFDA. 1 case is Marinol, an antiemetic agent indicated for nausea and vomiting associated with cancer.
Lots of healthcare professional societies and associations have voiced their own support. For instance, The American College of Physicians, advocated a re evaluation of this Schedule I classification of marijuana in their 2008 post newspaper. ACP also expresses its strong support for research to the therapeutic role of bud in addition to exemption from federal criminal prosecution; civil liability; or practitioner sanctioning for physicians who prescribe or dispense medical marijuana in accordance with law. Similarly, protection from civil or criminal penalties for patients who use medical marijuana as permitted under state laws.
(4) Medical marijuana is legally utilised in most developed countries The argument of if they’re able to do it, why not us? Is yet another strong point. Some countries, for example Canada, Belgium, Austria, the Netherlands, the United Kingdom, Spain, Israel, and Finland have resisted the therapeutic usage of marijuana under rigorous prescription management. Some nations in the usa may also be allowing exemptions.
(1) Lack of information on safety and efficiency. Medication regulation relies upon safety first. The security of marijuana and its ingredients still has to first be established. Efficacy just includes moment. Unless bud is demonstrated to be better (safer and more effective) than medication now available in the market, its own approval for medical use might be a very long shot. In accordance with the testimony of Robert J. Meyer of the Department of Health and Human Services having access to a medication or medical treatment, without focusing on just how to use it even if it is effective, will not benefit anybody. Only using access, without having safety, efficacy, and adequate use information doesn’t help patients.
(2) Unknown chemical components. Medical bud may be easily available and inexpensive in herbal type. As with other herbs, bud falls under the category of botanical products and services. UN purified botanical goods, however, face many issues for example lot-to-lot consistency, dose determination, potency, shelflife, and toxicity. To fully describe different components of marijuana will cost so much time and money that the costs of these medications that will come out of this will be overly large. Currently, no pharmaceutical company appears to be enthusiastic about investing cash to segregate more therapeutic components from bud outside what is available on the marketplace.
(3) Possible for misuse. Pot or cannabis is addictive. It might not be as addictive as hard drugs such as cocaine; yet it cannot be denied that there’s a possibility of chemical abuse connected with bud. This was attested by a few studies as summarized in the IOM report.
(4) Lack of a secure delivery technique. Considering the recent trends in antismoking legislations, this kind of delivery won’t ever be approved by health authorities. Reliable and secure delivery systems in the form of vaporizers, nebulizers, or inhalers continue to be at the testing stage.
Even if marijuana has therapeutic outcomes, it’s only addressing the symptoms of certain diseases. It can not cure or treat these disorders. Given that it is effective against such symptoms, you can find already medications available that work just as well and better still, minus the side effects and risk of abuse associated with marijuana.
The 1999 IOM report couldn’t settle the debate concerning medical marijuana with scientific evidence available at that time. The report clearly discouraged using smoked marijuana but gave a nod to marijuana usage through a medical inhaler or vaporizer. What’s more, it urged greater funding from the research of their safety and efficacy of cannabinoids.
So what stands in the means of Assessing the questions brought up by the IOM report? The health authorities don’t seem to be curious about having another review. There is limited data available and whatever is available is biased towards safety problems on the adverse effects of smoked marijuana. Data readily available on efficacy mainly come from studies on synthetic cannabinoids (e.g. THC). This disparity in statistics creates a goal risk-benefit appraisal difficult.
Clinical studies on bud are difficult to run due to limited funding and strict regulations. On account of the complicated legalities involved, not many pharmaceutical companies are purchasing cannabinoid research. In many cases, it’s not clear how to specify medical bud as advocated as opposed by many classes. Does it only refer to the utilization of the botanical product bud or does this contain artificial cannabinoid components (e.g. THC and derivatives) as well? Synthetic cannabinoids (e.g. Marinol) available in the market are incredibly expensive, forcing people towards the more affordable cannabinoid from the kind of marijuana. Obviously, the matter is further clouded by conspiracy theories between the pharmaceutical industry and drug regulators.